NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer to reality.
Longevity biotech NewLimit has secured an additional $45 million in funding from Eli Lilly, Duke University, S32 and other investors, at a valuation of $1.62 billion. The financing comes just five months after the company’s $130 million Series B round in May and follows recent “technical breakthroughs” that have accelerated its path toward human clinical studies.
Founded to extend human healthspan by addressing the biology of aging itself, NewLimit’s epigenetic reprogramming platform aims to restore youthful function to aged cells. The epigenome governs which genes are active in a cell, but its regulation deteriorates with age, leading to loss of cellular function and increased susceptibility to disease. By reprogramming these epigenetic patterns, the company seeks to rejuvenate cells and restore their youthful performance.
Given Lilly’s participation in the round, and the significant jump in valuation (reportedly double that of its Series B), the new progress made by NewLimit must be significant. Earlier this year, the company reported progress in two therapeutic areas – liver metabolism and immune cell rejuvenation – and more recently revealed that it has also expanded its focus to vascular health through a new program targeting endothelial cells.
“Advances in our lead program to restore youthful liver function now give us the confidence to start planning clinical studies in the next few years,” said NewLimit co-founder and head of research Jacob Kimmel in a LinkedIn post about the new funding.
Rejuvenating liver function
In its preclinical studies, NewLimit has previously demonstrated that its approach can restore youthful function to hepatocytes and immune cells. The company identified three transcription factor sets that showed efficacy in animal models of liver disease, as well as three that rejuvenated aged T cells, restoring their killing activity against target cells to levels observed in younger immune systems.
NewLimit’s latest update detailed the addition of two new prototype medicines demonstrating efficacy in preclinical liver disease models, 14 new transcription factor sets restoring youthful function in T cells, and eight more that achieve similar effects in hepatocytes. The company also revealed it is now screening for resilience – testing whether reprogramming interventions can make old cells more resistant to injury.
The new expansion into vascular biology marks a broadening of NewLimit’s therapeutic strategy. Endothelial cells, which line the body’s blood vessels, play a central role in tissue health and function across organ systems. With aging, these cells lose integrity and become more permeable, contributing to a wide range of age-related disorders, including renal, cardiovascular and cognitive decline. The company says its new vascular program initially targets endothelial dysfunction in aged kidneys, with the goal of restoring youthful vascular function and improving overall tissue health.
Having now secured more than $300 million in total funding, NewLimit is one of the most well-capitalized companies in the longevity biotechnology sector. We’ll be watching closely to see if investor confidence is justified as it joins companies like Life Biosciences in the quest to bring cellular rejuvenation therapeutics into clinical trials.
